A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.

A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34041735

about

Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma Quantification of CT-assessed radiation-induced lung damage in lung cancer patients treated with or without chemotherapy and cetuximab.miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer

P2860

Q26751346-5C661DC6-9861-4078-AC78-17055D6F1063 Q50559529-53BD81A8-38DA-4A39-9E71-ED60185BDCC9 Q52683993-03BEF8B4-E667-4279-B5BF-E56D0A050B05 Q58798338-4408BB28-345F-4489-A4A2-8F94DCB54FBB Q58804840-382E4DD7-4B42-4792-9E9D-FFAC3C2C4071

P2860

A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34041735

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase I study of concurrent ...... II non-small-cell lung cancer.

@ast

A phase I study of concurrent ...... II non-small-cell lung cancer.

@en

A phase I study of concurrent ...... II non-small-cell lung cancer.

@nl

type

label

A phase I study of concurrent ...... II non-small-cell lung cancer.

@ast

A phase I study of concurrent ...... II non-small-cell lung cancer.

@en

A phase I study of concurrent ...... II non-small-cell lung cancer.

@nl

prefLabel

A phase I study of concurrent ...... II non-small-cell lung cancer.

@ast

A phase I study of concurrent ...... II non-small-cell lung cancer.

@en

A phase I study of concurrent ...... II non-small-cell lung cancer.

@nl

P1433

Q34041735-9B3E5C7C-9440-481F-B49A-7A09DCD12C82

P1476

Q34041735-D21D2708-9700-4F94-888C-384006E83B2B

P2093

Q34041735-05848B96-1FF5-4C46-9C36-81EB87D1F173

Q34041735-062D077C-08A9-436A-A7AE-FC41114BF06B

Q34041735-06C3227A-ABE2-4F86-9CB2-55AD8D9ABB89

Q34041735-491C3E11-6749-4CC2-998E-1837E5BA65E6

Q34041735-4CEBE534-4F35-463E-9BF8-2FBBD6C85BB9

Q34041735-852B5351-EDF9-4DD6-9461-F1540EDFC65E

Q34041735-A25D703A-D33C-4820-9786-AAAA67419F3A

Q34041735-B783CF19-59B1-44D1-8B15-5AF0F815E32B

Q34041735-D1F66799-C89A-4B5A-8283-5A8E08E4AD09

Q34041735-D33ED07E-7887-4D95-837D-8080D021EB94

P2860

Q34041735-10C46F8D-B5FF-42B6-8664-4CEF6804F800

Q34041735-333537C5-CADB-4EB6-AA14-985074385A79

Q34041735-4441DFE5-1BCF-4EC1-AEBD-4D280C80C41A

Q34041735-4D025612-471E-40B4-A0F7-95F0D51D5E7F

Q34041735-5531F2F1-F865-4F14-8FE9-6BED3A0C3523

Q34041735-580BC951-0B10-45E4-BA8A-E07A21286EEB

Q34041735-5861ABB2-4086-432A-B808-919D03A93150

Q34041735-61B23B24-1529-44CE-8EDB-DEB88D5C3461

Q34041735-6ED39604-A3EF-444B-99FF-628BE504CFC2

Q34041735-7B3B2D43-4CFA-4C2F-AFE9-92F000A16967

P304

Q34041735-134F64FD-FE55-4B8F-8A2A-5D311C9E2CE2

P31

Q34041735-817079CD-BC55-4837-A430-6332E1997CEF

P356

Q34041735-B796D811-A00B-4633-B04D-2523FAF93336

P433

Q34041735-71EBAB73-0741-403E-8053-30D477E7E8EC

P478

Q34041735-F86F422A-F751-48EC-832A-175D0ECD7737

P50

Q34041735-FD9B861A-E668-4B6B-929E-8B17BF9356B7

P577

Q34041735-E5D40C10-153F-4657-AA5B-862E72E313C5

P698

Q34041735-4F845090-EE21-48E9-873D-6ED70DD8C598

P921

Q34041735-7C3A55CA-51BC-44FB-BA0B-975AE5C2DB41

P932

Q34041735-938DBDC1-EF12-474D-B9F3-0995AB09137F

P356

JTO.0000000000000151

P1433

Journal of Thoracic Oncology

P1476

A phase I study of concurrent ...... II non-small-cell lung cancer.

@en

P2093

Anne-Marie C Dingemans

http://www.w3.org/2001/XMLSchema#string

Arne van Belle

http://www.w3.org/2001/XMLSchema#string

Bart Reymen

http://www.w3.org/2001/XMLSchema#string

Boudewijn Brans

http://www.w3.org/2001/XMLSchema#string

Dirk de Ruysscher

http://www.w3.org/2001/XMLSchema#string

Gerben Bootsma

http://www.w3.org/2001/XMLSchema#string

Marco Das

http://www.w3.org/2001/XMLSchema#string

Monique Hochstenbag

http://www.w3.org/2001/XMLSchema#string

Philippe Lambin

http://www.w3.org/2001/XMLSchema#string

Rinus Wanders

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma

Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.

Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis

P304

710-716

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0000000000000151

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Angela van Baardwijk

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24722157

http://www.w3.org/2001/XMLSchema#string

P921

P932

4132032

http://www.w3.org/2001/XMLSchema#string